After a string of discouraging clinical trial results and slow sales, Abbott Laboratories Inc. is pulling the plug on the embattled Absorb bioabsorbable coronary stent.
Abbott Pulls Absorb Stent Off The Market, Citing Low Sales
Abbott is giving up on selling its first-generation biosorbable coronary stent, which failed to match the performance of contemporary metallic drug-eluting stents in clinical trials. The company says it will continue working on the next-generation biosorbable stents and continue the ongoing trials of Absorb GT1 BVS.